Elevar Therapeutics' drug lirafugratinib is now included in important U.S. treatment guidelines.

Nov 3, 2026, 7:08 PM ETTrialRead the original at globenewswire.com

Good for RLAY

Relay Therapeutics licensed lirafugratinib to Elevar, and the drug received a Category 2A place in NCCN cancer-care guidelines. U.S. availability is expected in Q4 2026, so sales have not yet been reported.

RLAY · Elevar Therapeutics

AI read · Good for RLAY

The AI's read

Recognition in a cancer-care guide may help doctors consider the treatment. Relay Therapeutics licensed the drug to Elevar, which holds worldwide sales rights. U.S. availability is expected in Q4 2026, and the source reports no sales or financial terms.

Get alerts for RLAY

Follow Elevar Therapeutics (RLAY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RLAY

Free on the App Store and Google Play, or on the web.